BIT 5.41% 3.9¢ biotron limited

This exert from the letter to shareholders October 2018:In...

  1. 125 Posts.
    lightbulb Created with Sketch. 47
    This exert from the letter to shareholders October 2018:
    In coming weeks, Biotron will brief potential
    pharmaceutical partners on the trial outcomes. We
    believe that the successful results from this study will
    facilitate commercialisation negotiations with these
    parties.

    And this from the letter to shareholders September 2023:
    Biotron expects to have data from three such
    trials available in the very near term which puts
    the Company in a very strong position. These
    data, if positive, will be central to successfully
    negotiating and completing a commercial
    transaction for the Company’s HIV‐1 and
    COVID‐19 clinical programs.

    Good luck to us all!!
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
3.9¢
Change
0.002(5.41%)
Mkt cap ! $34.28M
Open High Low Value Volume
3.7¢ 3.9¢ 3.7¢ $27.73K 718.7K

Buyers (Bids)

No. Vol. Price($)
1 515504 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 100000 1
View Market Depth
Last trade - 11.51am 28/06/2024 (20 minute delay) ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.